{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:40:50Z","timestamp":1794656450360,"version":"4.9.1"},"reference-count":119,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100013314","name":"Higher Education Discipline Innovation Project","doi-asserted-by":"publisher","award":["D16013"],"award-info":[{"award-number":["D16013"]}],"id":[{"id":"10.13039\/501100013314","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901811"],"award-info":[{"award-number":["81901811"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["42388101"],"award-info":[{"award-number":["42388101"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["92256203"],"award-info":[{"award-number":["92256203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.critrevonc.2025.105064","type":"journal-article","created":{"date-parts":[[2025,11,29]],"date-time":"2025-11-29T16:03:04Z","timestamp":1764432184000},"page":"105064","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["AI-enhanced synergistic chemo-immunotherapy: From mechanistic insights to clinical translation"],"prefix":"10.1016","volume":"217","author":[{"given":"Sajid","family":"Muhammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenda","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hina","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41571-023-00830-6","article-title":"Computational immunogenomic approaches to predict response to cancer immunotherapies","volume":"21","author":"Addala","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib2","doi-asserted-by":"crossref","first-page":"4006","DOI":"10.1038\/ncomms5006","article-title":"Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach","volume":"5","author":"Aerts","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2025.105064_bib3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/978-981-15-3266-5_3","article-title":"Roles of PD-1\/PD-L1 pathway: signaling, cancer, and beyond","volume":"1248","author":"Ai","year":"2020","journal-title":"Adv. Exp. Med Biol."},{"issue":"Pt 2","key":"10.1016\/j.critrevonc.2025.105064_bib4","article-title":"A comprehensive review of immune checkpoint inhibitors for cancer treatment","volume":"143","author":"Arafat Hossain","year":"2024","journal-title":"Int. Immunopharmacol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105064_bib5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S1470-2045(23)00462-X","article-title":"A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis","volume":"24","author":"Arthur","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105064_bib6","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/cancers12041047","article-title":"Current approaches for combination therapy of cancer: the role of immunogenic cell death","volume":"12","author":"Asadzadeh","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib8","doi-asserted-by":"crossref","first-page":"9527","DOI":"10.2147\/OTT.S224013","article-title":"Blocking TGF-\u03b2 signaling to enhance the efficacy of immune checkpoint inhibitor","volume":"12","author":"Bai","year":"2019","journal-title":"Onco Targets Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib9","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2022.2120676","article-title":"Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness","volume":"11","author":"Barnestein","year":"2022","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2019.12.010","article-title":"Resistance to checkpoint inhibition in cancer immunotherapy","volume":"13","author":"Barrueto","year":"2020","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib11","series-title":"Drug Resistance in Cancer: Mechanisms and Strategies","first-page":"31","article-title":"Mechanisms of Cancer Resistance to Various Therapies","author":"Batool","year":"2024"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00262-021-03013-3","article-title":"Chemotherapy: a double-edged sword in cancer treatment","volume":"71","author":"Behranvand","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105064_bib13","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.7150\/ijbs.93697","article-title":"Using Combination therapy to overcome diverse challenges of Immune Checkpoint Inhibitors treatment","volume":"20","author":"Birnboim-Perach","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.critrevonc.2025.105064_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103630","volume":"73","author":"Boudou-Rouquette","year":"2021","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","article-title":"Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy","volume":"16","author":"Cai","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","article-title":"Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors","volume":"22","author":"Catanzaro","year":"2025","journal-title":"Cell Mol. Immunol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105064_bib17","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1080\/14712598.2022.2116273","article-title":"Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives","volume":"22","author":"Cella","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ccell.2025.02.010","article-title":"Low-dose irradiation of the gut improves the efficacy of PD-L1 blockade in metastatic cancer patients","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell"},{"issue":"15","key":"10.1016\/j.critrevonc.2025.105064_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000025180","article-title":"Comparison of atezolizumab, durvalumab, pembrolizumab, and nivolumab as first-line treatment in patients with extensive-stage small cell lung cancer: A systematic review and network meta-analysis","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105064_bib20","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","article-title":"Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial","volume":"19","author":"Choueiri","year":"2018","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105064_bib21","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-019-0583-3","article-title":"Deep learning-based classification of mesothelioma improves prediction of patient outcome","volume":"25","author":"Courtiol","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.critrevonc.2025.105064_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1200646","article-title":"Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy","volume":"13","author":"Czajka-Francuz","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211034366","article-title":"New approaches and procedures for cancer treatment: current perspectives","volume":"9","author":"Debela","year":"2021","journal-title":"SAGE Open Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s44387-025-00044-4","article-title":"The AI revolution: how multimodal intelligence will reshape the oncology ecosystem","volume":"1","author":"Dellamonica","year":"2025","journal-title":"npj Artif. Intell."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105064_bib25","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/S0959-8049(01)00184-8","article-title":"T Lymphocytes infiltrating various tumour types express the MHC class II ligand lymphocyte activation gene-3 (LAG-3): role of LAG-3\/MHC class II interactions in cell-cell contacts","volume":"37","author":"Demeure","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105064_bib26","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00262-015-1771-8","article-title":"Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors","volume":"65","author":"Derer","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105064_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41591-021-01655-5","article-title":"Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer","volume":"28","author":"Derosa","year":"2022","journal-title":"Nat. Med."},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105064_bib28","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.3390\/cancers14163876","article-title":"Predictive biomarkers of response to neoadjuvant chemotherapy in breast cancer: current and future perspectives for precision medicine","volume":"14","author":"Derouane","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib29","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2437918","article-title":"Immunogenic cell death: a new strategy to enhancing cancer immunotherapy","volume":"20","author":"Dou","year":"2024","journal-title":"Hum. Vaccin Immunother."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105064_bib30","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1373\/clinchem.2019.303644","article-title":"Biomarkers for predicting response to immunotherapy with immune checkpoint inhibitors in cancer patients","volume":"65","author":"Duffy","year":"2019","journal-title":"Clin. Chem."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib31","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/s41591-024-03408-6","article-title":"Nationwide real-world implementation of AI for cancer detection in population-based mammography screening","volume":"31","author":"Eisemann","year":"2025","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib32","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1158\/0008-5472.CAN-20-1818","article-title":"Cyclophosphamide and vinorelbine activate stem-like CD8(+) T cells and improve anti-PD-1 efficacy in triple-negative breast cancer","volume":"81","author":"Falvo","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105064_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1571212","article-title":"Regulation of immunogenic cell death and potential applications in cancer therapy","volume":"16","author":"Fang","year":"2025","journal-title":"Front Immunol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib34","first-page":"252","article-title":"A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy","volume":"3","author":"Fujiwara","year":"2020","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.critrevonc.2025.105064_bib35","doi-asserted-by":"crossref","first-page":"vi33","DOI":"10.1093\/annonc\/mdz326","article-title":"SY7-1 - tumor and host factors regulating anti-tumor immunity and immunotherapy efficacy","volume":"30","author":"Gajewski","year":"2019","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.105064_bib36","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.105064_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers"},{"issue":"39","key":"10.1016\/j.critrevonc.2025.105064_bib38","doi-asserted-by":"crossref","first-page":"41600","DOI":"10.18632\/oncotarget.6113","article-title":"Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies","volume":"6","author":"Gebremeskel","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1586\/1744666X.2014.865520","article-title":"The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy","volume":"10","author":"Ghiringhelli","year":"2014","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105064_bib40","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1021\/acsbiomaterials.5c00121","article-title":"In situ cancer vaccines: redefining immune activation in the tumor microenvironment","volume":"11","author":"Giram","year":"2025","journal-title":"ACS Biomater. Sci. Eng."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105064_bib41","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib42","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s12672-025-03307-3","article-title":"Application of artificial intelligence in medical imaging for tumor diagnosis and treatment: a comprehensive approach","volume":"16","author":"Huang","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"41","key":"10.1016\/j.critrevonc.2025.105064_bib44","doi-asserted-by":"crossref","first-page":"17218","DOI":"10.1039\/D1NR05512G","article-title":"Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy","volume":"13","author":"Jiang","year":"2021","journal-title":"Nanoscale"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib45","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41573-022-00615-z","article-title":"Rational combinations of targeted cancer therapies: background, advances and challenges","volume":"22","author":"Jin","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.critrevonc.2025.105064_bib46","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s42490-019-0026-8","article-title":"An automatic nuclei segmentation method based on deep convolutional neural networks for histopathology images","volume":"1","author":"Jung","year":"2019","journal-title":"BMC Biomed. Eng."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105064_bib47","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib48","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/immuno5030032","article-title":"Cancer resistance to immunotherapy","volume":"5","author":"Khoury","year":"2025","journal-title":"Immuno"},{"key":"10.1016\/j.critrevonc.2025.105064_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.110727","article-title":"High-throughput screening system for immunogenic cell death inducers using artificial intelligence-based real-time image analysis","volume":"196","author":"Kim","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.critrevonc.2025.105064_bib50","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2021.09.013","article-title":"Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: a review","volume":"158","author":"Larroquette","year":"2021","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12943-021-01317-7","article-title":"Chemotherapeutic and targeted agents can modulate the tumor microenvironment and increase the efficacy of immune checkpoint blockades","volume":"20","author":"Li","year":"2021","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib52","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib53","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib54","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.critrevonc.2025.105064_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.747194","article-title":"Integrating molecular biomarker inputs into development and use of clinical cancer therapeutics","volume":"12","author":"Louie","year":"2021","journal-title":"Front. Pharm."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15030708","article-title":"The use of artificial intelligence in the diagnosis and classification of thyroid nodules: an update","volume":"15","author":"Ludwig","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.105064_bib57","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canlet.2019.04.017","article-title":"Emerging strategies in cancer therapy combining chemotherapy with immunotherapy","volume":"454","author":"Luo","year":"2019","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib58","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2025.105064_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1612567","article-title":"Nutritional status, immunonutrition, and gut microbiome: a coming of age for immunotherapy?","volume":"16","author":"Mattavelli","year":"2025","journal-title":"Front. Immunol."},{"issue":"7788","key":"10.1016\/j.critrevonc.2025.105064_bib60","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41586-019-1799-6","article-title":"International evaluation of an AI system for breast cancer screening","volume":"577","author":"McKinney","year":"2020","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105064_bib61","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1007\/s00262-008-0505-6","article-title":"Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity","volume":"57","author":"M\u00e9nard","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.105064_bib62","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.105064_bib63","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clnesp.2024.09.002","article-title":"Relationship between energetic gap and sensitivity to anti-programmed cell death 1 immune checkpoint inhibitors in non-small cell lung cancer patients: the ELY-2 study","volume":"64","author":"Meyo","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105064_bib64","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1111\/bcp.14352","article-title":"Immune checkpoint blockade in solid organ tumours: Choice, dose and predictors of response","volume":"86","author":"Navani","year":"2020","journal-title":"Br. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75589-6","article-title":"Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy","volume":"14","author":"Nikitas","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.critrevonc.2025.105064_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1483834","article-title":"The complex role of immune cells in antigen presentation and regulation of T-cell responses in hepatocellular carcinoma: progress, challenges, and future directions","volume":"15","author":"Ning","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/diseases13010024","article-title":"Integrating AI into cancer immunotherapy-a narrative review of current applications and future directions","volume":"13","author":"Olawade","year":"2025","journal-title":"Diseases"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/ph15030335","article-title":"Revolutionization in cancer therapeutics via targeting major immune checkpoints PD-1, PD-L1 and CTLA-4","volume":"15","author":"Pandey","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105064_bib69","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/S2589-7500(20)30159-X","article-title":"An artificial intelligence algorithm for prostate cancer diagnosis in whole slide images of core needle biopsies: a blinded clinical validation and deployment study","volume":"2","author":"Pantanowitz","year":"2020","journal-title":"Lancet Digit Health"},{"issue":"17","key":"10.1016\/j.critrevonc.2025.105064_bib70","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1200\/JCO.21.02010","article-title":"Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as complementary biomarker for immune checkpoint inhibition in non-small-cell lung cancer","volume":"40","author":"Park","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"1160","key":"10.1016\/j.critrevonc.2025.105064_bib71","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1093\/bjr\/tqae100","article-title":"Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy","volume":"97","author":"Passelli","year":"2024","journal-title":"Br. J. Radio."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib72","first-page":"46","article-title":"AI-driven insights into the microbiota: Figuring out the mysterious world of the gut","volume":"3","author":"Patil","year":"2025","journal-title":"Intell. Pharm."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105064_bib73","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/s41591-023-02332-5","article-title":"A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories","volume":"29","author":"Placido","year":"2023","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib74","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00262-012-1390-6","article-title":"Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer","volume":"62","author":"Ramakrishnan","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.105064_bib75","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/MNM.0000000000000997","article-title":"Quantification of global lung inflammation using volumetric 18F-FDG PET\/CT parameters in locally advanced non-small-cell lung cancer patients treated with concurrent chemoradiotherapy: a comparison of photon and proton radiation therapy","volume":"40","author":"Rice","year":"2019","journal-title":"Nucl. Med. Commun."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202402117","article-title":"Synthesis, aromatase inhibition, cytotoxicity and molecular docking studies of new fluorinated and non-fluorinated thiourea derivatives of desloratadine","volume":"22","author":"Sajid","year":"2025","journal-title":"Chem. Biodivers."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.105064_bib77","doi-asserted-by":"crossref","first-page":"11761","DOI":"10.1007\/s00210-025-04125-8","article-title":"Chemoimmunotherapy synergism: mechanisms and clinical applications","volume":"398","author":"Shaik","year":"2025","journal-title":"Naunyn Schmiede Arch. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105064_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1355387","article-title":"Systematic review on the role of the gut microbiota in tumors and their treatment","volume":"15","author":"Shi","year":"2024","journal-title":"Front. Endocrinol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105064_bib79","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib80","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.critrevonc.2017.03.003","article-title":"Combination of immune checkpoint inhibitors and radiotherapy: review of the literature","volume":"113","author":"Sindoni","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2147\/OTT.S122974","article-title":"nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors","volume":"10","author":"Soliman","year":"2017","journal-title":"Onco Targets Ther."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105064_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15112912","article-title":"Chemo-immunotherapy: a new trend in cancer treatment","volume":"15","author":"Sordo-Bahamonde","year":"2023","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105064_bib83","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S2468-1253(21)00215-6","article-title":"Computer-aided detection versus advanced imaging for detection of colorectal neoplasia: a systematic review and network meta-analysis","volume":"6","author":"Spadaccini","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib84","article-title":"Application progress of artificial intelligence in tumor diagnosis and treatment","volume":"7","author":"Sun","year":"2024","journal-title":"Front Artif. Intell."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib85","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.critrevonc.2025.105064_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsm.2025.02.004","article-title":"Unlocking the power of machine learning in big data: a scoping survey","author":"Surur","year":"2025","journal-title":"Data Sci. Manag."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib87","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2025.2507856","article-title":"Updates on radiotherapy-immunotherapy combinations: proceedings of 8th Annual ImmunoRad Conference","volume":"14","author":"Talebi","year":"2025","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib88","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12943-025-02369-9","article-title":"Current AI technologies in cancer diagnostics and treatment","volume":"24","author":"Tiwari","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.critrevonc.2025.105064_bib89","doi-asserted-by":"crossref","first-page":"895","DOI":"10.3389\/fimmu.2020.00895","article-title":"A new strategy toward B cell-based cancer vaccines by active immunization with mimotopes of immune checkpoint inhibitors","volume":"11","author":"Tobias","year":"2020","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.105064_bib90","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000038088","article-title":"Mechanisms of microbiota modulation: Implications for health, disease, and therapeutic interventions","volume":"103","author":"Ugwu","year":"2024","journal-title":"Medicine"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib91","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.critrevonc.2025.105064_bib92","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-981-15-3266-5_2","article-title":"Molecular and cellular functions of CTLA-4","volume":"1248","author":"Van Coillie","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030627","article-title":"Chemotherapy side-effects: not all DNA damage is equal","volume":"14","author":"van den Boogaard","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib94","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1084\/jem.190.3.355","volume":"190","author":"van Elsas","year":"1999","journal-title":"J. Exp. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105064_bib95","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040935","article-title":"Future challenges in cancer resistance to immunotherapy","volume":"12","author":"van Elsas","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105064_bib96","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2025.105064_bib97","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.1158\/1078-0432.CCR-20-0071","article-title":"Prognostic significance of immune cell populations identified by machine learning in colorectal cancer using routine hematoxylin and eosin-stained sections","volume":"26","author":"V\u00e4yrynen","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"48","key":"10.1016\/j.critrevonc.2025.105064_bib98","doi-asserted-by":"crossref","first-page":"5418","DOI":"10.3748\/wjg.v24.i48.5418","article-title":"Colorectal cancer vaccines: Tumor-associated antigens vs neoantigens","volume":"24","author":"Wagner","year":"2018","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib99","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","article-title":"Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"2025","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.105064_bib100","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1158\/0008-5472.CAN-19-1629","article-title":"Computational staining of pathology images to study the tumor microenvironment in lung cancer","volume":"80","author":"Wang","year":"2020","journal-title":"Cancer Res."},{"issue":"8035","key":"10.1016\/j.critrevonc.2025.105064_bib101","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1038\/s41586-024-07894-z","article-title":"A pathology foundation model for cancer diagnosis and prognosis prediction","volume":"634","author":"Wang","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib102","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastas. Rev."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105064_bib103","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1109\/TMI.2021.3078067","article-title":"DRONE: Dual-Domain Residual-based Optimization NEtwork for Sparse-View CT Reconstruction","volume":"40","author":"Wu","year":"2021","journal-title":"IEEE Trans. Med. Imaging"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.105064_bib104","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11060-019-03172-5","article-title":"Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment","volume":"143","author":"Wu","year":"2019","journal-title":"J. Neurooncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib105","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12951-021-01181-z","article-title":"Nanomedicine-enabled chemotherapy-based synergetic cancer treatments","volume":"20","author":"Wu","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib106","article-title":"Modulation of gut microbiota to enhance effect of checkpoint inhibitor immunotherapy","volume":"12","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib107","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1186\/s12967-024-05609-6","article-title":"Artificial intelligence: illuminating the depths of the tumor microenvironment","volume":"22","author":"Xie","year":"2024","journal-title":"J. Transl. Med."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.105064_bib108","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.apsb.2021.02.007","article-title":"Applying artificial intelligence for cancer immunotherapy","volume":"11","author":"Xu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.critrevonc.2025.105064_bib109","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.3389\/fimmu.2018.01739","article-title":"Combining immune checkpoint inhibitors with conventional cancer therapy","volume":"9","author":"Yan","year":"2018","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.105064_bib110","first-page":"4105","article-title":"Present and future of cancer immunotherapy: a tumor microenvironmental perspective","volume":"16","author":"Yu","year":"2018","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.105064_bib111","article-title":"Artificial intelligence and multi-omics in pharmacogenomics: a new era of precision medicine","volume":"3","author":"Zack","year":"2025","journal-title":"Mayo Clin. Proc. Digit. Health"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.105064_bib112","doi-asserted-by":"crossref","first-page":"6596","DOI":"10.1096\/fj.201802067RR","article-title":"Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment","volume":"33","author":"Zeng","year":"2019","journal-title":"Faseb J."},{"key":"10.1016\/j.critrevonc.2025.105064_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.594609","article-title":"Cytokine and chemokine signals of T-cell exclusion in tumors","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib114","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.3389\/fphar.2019.01184","article-title":"Safety and efficacy of therapeutic cancer vaccines alone or in combination with immune checkpoint inhibitors in cancer treatment","volume":"10","author":"Zhao","year":"2019","journal-title":"Front. Pharm."},{"key":"10.1016\/j.critrevonc.2025.105064_bib115","article-title":"Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib116","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41392-024-01823-2","article-title":"Tumor biomarkers for diagnosis, prognosis and targeted therapy","volume":"9","author":"Zhou","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.105064_bib117","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/path.6263","article-title":"AI-guided histopathology predicts brain metastasis in lung cancer patients","volume":"263","author":"Zhou","year":"2024","journal-title":"J. Pathol."},{"key":"10.1016\/j.critrevonc.2025.105064_bib118","article-title":"Artificial intelligence in the radiomic analysis of glioblastomas: a review, taxonomy, and perspective","volume":"12","author":"Zhu","year":"2022","journal-title":"Front Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.105064_bib119","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1038\/s41591-025-03804-6","article-title":"Rethinking chemotherapy as an indirect vaccine","volume":"31","author":"Zitvogel","year":"2025","journal-title":"Nat. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825004524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T01:08:00Z","timestamp":1773882480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825004524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":119,"alternative-id":["S1040842825004524"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105064","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AI-enhanced synergistic chemo-immunotherapy: From mechanistic insights to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.105064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105064"}}